Renaissance Technologies LLC Sells 263,400 Shares of Alexion Pharmaceuticals, Inc. (ALXN)

Renaissance Technologies LLC reduced its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 59.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 178,800 shares of the biopharmaceutical company’s stock after selling 263,400 shares during the quarter. Renaissance Technologies LLC’s holdings in Alexion Pharmaceuticals were worth $21,383,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. Geode Capital Management LLC raised its holdings in Alexion Pharmaceuticals by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 2,256,415 shares of the biopharmaceutical company’s stock worth $269,251,000 after purchasing an additional 62,266 shares during the period. UBS Asset Management Americas Inc. raised its holdings in Alexion Pharmaceuticals by 10.3% in the 4th quarter. UBS Asset Management Americas Inc. now owns 1,871,548 shares of the biopharmaceutical company’s stock worth $223,818,000 after purchasing an additional 174,606 shares during the period. Wells Fargo & Company MN raised its holdings in Alexion Pharmaceuticals by 32.7% in the 3rd quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock worth $218,647,000 after purchasing an additional 383,713 shares during the period. Bank of Montreal Can raised its holdings in Alexion Pharmaceuticals by 21.4% in the 4th quarter. Bank of Montreal Can now owns 1,521,834 shares of the biopharmaceutical company’s stock worth $181,998,000 after purchasing an additional 268,053 shares during the period. Finally, Temasek Holdings Private Ltd raised its holdings in Alexion Pharmaceuticals by 3.6% in the 3rd quarter. Temasek Holdings Private Ltd now owns 1,505,325 shares of the biopharmaceutical company’s stock worth $211,182,000 after purchasing an additional 52,403 shares during the period. 95.36% of the stock is currently owned by institutional investors.

How to Become a New Pot Stock Millionaire

A number of brokerages recently commented on ALXN. Evercore ISI raised Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a report on Monday, February 5th. Nomura raised their target price on Alexion Pharmaceuticals from $148.00 to $156.00 and gave the stock a “buy” rating in a report on Thursday, March 15th. Robert W. Baird set a $160.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, March 15th. Leerink Swann decreased their target price on Alexion Pharmaceuticals from $166.00 to $153.00 and set an “outperform” rating on the stock in a report on Friday, February 9th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $130.00 target price (down from $178.00) on shares of Alexion Pharmaceuticals in a report on Thursday, January 4th. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and twenty-one have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $155.22.

Alexion Pharmaceuticals, Inc. (ALXN) opened at $110.79 on Monday. The firm has a market capitalization of $24,560.08, a PE ratio of 21.85, a PEG ratio of 1.03 and a beta of 1.13. The company has a current ratio of 3.10, a quick ratio of 2.62 and a debt-to-equity ratio of 0.34. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.09 by $0.39. The firm had revenue of $909.70 million during the quarter, compared to analyst estimates of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.26 earnings per share. sell-side analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current year.

In other news, CFO Paul J. Clancy sold 6,079 shares of the firm’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $116.31, for a total transaction of $707,048.49. Following the completion of the transaction, the chief financial officer now owns 95,093 shares in the company, valued at $11,060,266.83. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Ludwig Hantson sold 2,553 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total value of $310,521.39. Following the transaction, the chief executive officer now owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 31,253 shares of company stock valued at $3,656,229. Company insiders own 4.35% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Renaissance Technologies LLC Sells 263,400 Shares of Alexion Pharmaceuticals, Inc. (ALXN)” was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3301628/renaissance-technologies-llc-sells-263400-shares-of-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

RSP Permian  Given a $69.00 Price Target by Stephens Analysts
RSP Permian Given a $69.00 Price Target by Stephens Analysts
Sandler O’Neill Analysts Give Simmons First National  a $35.00 Price Target
Sandler O’Neill Analysts Give Simmons First National a $35.00 Price Target
Wells Fargo Downgrades Emergent BioSolutions  to Market Perform
Wells Fargo Downgrades Emergent BioSolutions to Market Perform
Targa Resources  PT Set at $53.00 by Seaport Global Securities
Targa Resources PT Set at $53.00 by Seaport Global Securities
Cognex  Raised to Buy at Zacks Investment Research
Cognex Raised to Buy at Zacks Investment Research
Gold Corporation Barrick Buys 1,293,324 Shares of Royal Road Minerals  Stock
Gold Corporation Barrick Buys 1,293,324 Shares of Royal Road Minerals Stock


© 2006-2018 Ticker Report. Google+.